Growth • Gilead Sciences
GILD
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
5,1%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
19,6%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-38,3%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-38,2%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
5,2%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
3,4%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!